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Objective: To investigate the impact of HPV status in patients with locally advanced head and neck squa-
mous cell carcinoma (HNSCC), who received surgery and cisplatin-based postoperative radiochemother-
apy.
Materials and methods: For 221 patients with locally advanced squamous cell carcinoma of the hypophar-
ynx, oropharynx or oral cavity treated at the 8 partner sites of the German Cancer Consortium, the impact
of HPV DNA, p16 overexpression and p53 expression on outcome were retrospectively analysed. The
primary endpoint was loco-regional tumour control; secondary endpoints were distant metastases and
overall survival.
Results: In the total patient population, univariate analyses revealed a signiﬁcant impact of HPV16 DNA
positivity, p16 overexpression, p53 positivity and tumour site on loco-regional tumour control. Multivar-
iate analysis stratiﬁed for tumour site showed that positive HPV 16 DNA status correlated with loco-
regional tumour control in patients with oropharyngeal carcinoma (p = 0.02) but not in the oral cavity
carcinoma group. Multivariate evaluation of the secondary endpoints in the total population revealed a
signiﬁcant association of HPV16 DNA positivity with overall survival (p < 0.01) but not with distant
metastases.niversity
318 HPV16 DNA status and loco-regional control after PORT-C in HNSCCConclusions: HPV16 DNA status appears to be a strong prognosticator of loco-regional tumour control
after postoperative cisplatin-based radiochemotherapy of locally advanced oropharyngeal carcinoma
and is now being explored in a prospective validation trial.
 2014 Elsevier Ireland Ltd. Radiotherapy and Oncology 113 (2014) 317–323 This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Head and neck squamous cell carcinoma (HNSCC) patients have
a 5-year survival of approximately 50% [1,2]. Within the last years,
the number of oropharyngeal cancers has increased [3–5]. Postop-
erative radiotherapy (PORT) with concurrent cisplatin (PORT-C)
has become standard for the adjuvant treatment of patients with
resected locally advanced HNSCC after three randomised trials
showing superior loco-regional control and improved survival
rates compared to PORT alone [6–8]. A meta-analysis of two of
the above mentioned trials, the EORTC and the RTOG trials, con-
cluded that patients with positive microscopic resection margins
and/or extracapsular extension (ECE) from neck nodes beneﬁt most
from this combined treatment [9]. However, all three trials also
report increased toxicity after PORT-C vs. PORT [6–8].
In recent years, infection with high-risk human papillomavirus
(HPV) has been implicated in the pathogenesis of HNSCC, indepen-
dently of the risk factors smoking and alcohol consumption [10].
On the molecular level, the HPV oncogenes E6 and E7 have been
shown to drive carcinogenesis, which is accompanied by degrada-
tion of p53 and pRB and overexpression of p16 due to loss of its
transcriptional repression. In addition, HPV-related HNSCC show
less p53 mutations than smoking and alcohol induced HNSCC
[11]. HPV-positive tumours most commonly originate from the
oropharynx [12,13]; high-grade histology and positive lymph
nodes are frequent [14]. Interestingly, a recent study observed that
patients with HPV16 DNA positive oropharyngeal carcinoma and
lower levels of comorbidity show a signiﬁcantly better overall sur-
vival compared to patients with HPV16 DNA negative tumours
[15]. Speciﬁcally for the ﬁeld of Radiation Oncology, it has been
shown that HPV-positivity is a strong prognostic marker for overall
survival and/or local tumour control in patients treated with pri-
mary radiochemotherapy [16–20]. However, its impact on out-
come after PORT-C is not well evaluated so far.
In an ongoing multicentre retrospective – prospective trial con-
ducted by the Radiation Oncology Group of the German Cancer
Consortium (DKTK-ROG), biomarkers for stratiﬁcation of patients
for dose of primary or postoperative radiochemotherapy of HNSCC
are being evaluated. The present publication reports the impact of
HPV infection on loco-regional tumour control and survival after
PORT-C in the multicentre explorative cohort.Material and methods
Patients, treatment and tissue samples
Patients meeting the following criteria were eligible for inclu-
sion in this retrospective study: histologically proven squamous
cell carcinoma arising from the hypopharynx, oropharynx or oral
cavity, treatment between 2005 and 2010 with a curatively
intended cisplatin-based PORT-C according to standard protocols
covering the former tumour region and the neck nodes. All patients
had to be judged as being at high risk for loco-regional recurrence
due to locally advanced disease with a tumour stage pT4 and/or >3
positive lymph nodes and/or due to postoperative residual disease
(positive microscopic resection margins and/or extracapsular
spread). Minimum follow-up of patients without progressive dis-
ease had to be 24 months. Additionally, formalin-ﬁxed parafﬁn-
embedded (FFPE) material, radiotherapy treatment plans, CT, MRI
or PET–CT images of the localisation of the recurrent tumours as
well as follow-up data of patients had to be available. Smoking sta-tus and alcohol consumption were not consistently recorded for all
patients and therefore could not be analysed. It was aimed to
include 40 patients per DKTK partner centre (i.e., 320 patients in
total). To enhance the proportion of HPV-positivity, patients were
included consecutively backwards from 2010 towards 2005 in all
centres, as HPV prevalence in HNSCC is increasing in recent years
[21]. Finally, 221 patients were found to meet all requirements.
Those patients were evaluated in this study (Table 2). Pathological
specimens, radiotherapy treatment plans, radiological images of
recurrent tumours and follow-up data of patients were centrally
collected in the DKTK RadPlanBio Platform [Skripcak et al., manu-
script in preparation] at the DKTK partner site Dresden.
Ethical approval for multicentre retrospective analyses of clini-
cal and biological data was obtained by the Ethics Committees of
all DKTK partner sites.
Failure pattern analysis
Disease status and ﬁrst site of relapse were evaluated by the
treating institution (loco-regional failure, distant failure or com-
bined failure). When loco-regional recurrence and distant metasta-
ses occurred at the same time (maximally 6 weeks difference), the
patient was counted as combined failure. For every reported loco-
regional failure, the radiotherapy treatment plan and radiological
images of the recurrence (CT, MRI or PET–CT) were centrally
reviewed to ensure that failures originated from the irradiated
volume.Preparation of biomaterials for biomarker analyses
FFPE blocks of the primary tumours were centrally collected at
the DKTK partner site Dresden where slides for immunohisto-
chemistry were prepared and genomic DNA was extracted (vide
infra). In parallel tissue microarrays, RNA isolates and cDNA were
generated for further investigations of biomarkers, which are cur-
rently ongoing at the different partner sites. HPV DNA, p16 and p53
reported in this article were evaluated at the DKTK partner site
Dresden.Immunohistochemical staining of p16
In all FFPE samples, the squamous cell carcinoma content was
estimated from haematoxylin and eosin stained tissue sections
and FFPE samples with <10% tumour content were excluded from
p16 analysis. Two hundred and fourteen of the 221 tumour sam-
ples (60 oral cavity, 121 oropharynx, 33 hypopharynx) were evalu-
able for p16. Immunohistochemical staining was performed using
the CINtec Histology Kit (Roche mtm laboratories AG, Basel, CH)
according to the manufacturer’s instruction. Overexpression of
p16 was deﬁned as P70% intense tumour staining [16]. Blinded
samples were evaluated semi-quantitatively by two independent
observers (A.L. and C.v.N.) with an inter-observer variability of <5%.Immunohistochemical staining of p53
FFPE material from all 221 patients was available for p53 anal-
ysis. Following deparafﬁnisation and antigen retrieval in target
retrieval solution (pH 9; Dako, Glostrup, DK) for 35 min at
630W, immunohistochemical staining was performed. Endoge-
nous peroxidase activity was blocked (Peroxidase Block, Dako).
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human p53 antibody (Clone DO-7; Dako) in Dako REAL Antibody
Diluent for 30 min. Negative control slides were incubated with
corresponding IgG antibody control (Dako). The staining was visu-
alised by DAB immunostaining (Dako REAL EnVision Detection
System, Peroxidase/DAB, Rabbit/Mouse). Blinded samples were
evaluated semi-quantitatively by two independent observers
(A.L. and C.v.N.) with an inter-observer variability of <5%. Percent-
age of p53 staining [22] and staining intensity were scored (0, +, ++,
+++). Tumours with P70% positive nuclei and moderate (++) or
strong (+++) staining intensities were considered as p53 positive.DNA extraction and PCR array-based analysis of HPV status
Genomic DNA was extracted from 5 lm FFPE-sections using the
QIAamp DNA FFPE tissue kit (Qiagen GmbH, Hilden, DE) according
to the manufacturer’s instruction and stored at 20 C until
required. HPV DNA analyses including genotyping were carried
out using the LCD-Array HPV 3.5 kit (CHIPRON GmbH, Berlin, DE)
according to the manufacturer’s instruction. Brieﬂy, PCR was per-
formed using the provided Primer Mix A (My 11/09) and B
(‘125’) and the HotStarTaq Plus Master Mix (Qiagen GmbH).
Hybridisation mix including 5 ll of each ampliﬁed PCR product A
and B were added to each ﬁeld of the LCD-Array. After staining
and washing, the hybridisation spots were scanned and analysed
using the SlideReader Software (CHIPRON GmbH). For internal
quality control purposes, a positive control (HPV33 DNA, UT-SCC-
45 xenograft) and a negative control (RNase free water; Qiagen
GmbH) were included in each array. Six tissue samples had to be
omitted from HPV DNA analysis due to too low DNA yield, thus
215 of the 221 tumour samples (58 oral cavity, 123 oropharynx,
34 hypopharynx) were evaluable for HPV-PCR array.Statistics
The primary endpoint was loco-regional tumour control; free-
dom from distant metastases and overall survival were evaluated
as secondary endpoints. Loco-regional tumour control, distant
metastases and overall survival were calculated from the ﬁrst
day of radiotherapy to the date of local or regional recurrence, date
of metastases and date of death or last follow-up, respectively. All
endpoints were estimated with the Kaplan–Meier method. The
impact of potential prognosticators on the endpoints was evalu-
ated using the Cox-regression model. Parameters found to be sig-
niﬁcant in univariate analysis were included in a multivariate
Cox model. Statistical analyses were performed for all patients
and for the subgroups of patients with oral cavity cancers as well
as oropharyngeal cancers. Patients diagnosed with hypopharyn-
geal cancers were excluded from this subgroup analysis due to
the low number of cases. Sensitivity and speciﬁcity of p16 and
HPV16 DNA for predicting loco-regional recurrence were deter-
mined by cross tabulation. For all analyses, two-sided tests were
used and p-values <0.05 were considered statistically signiﬁcant.
SPSS 21 software (IBM Corporation, Armonk, NY, USA) was used
for the generation of Kaplan–Meier plots. STATA 11 (StataCorp
LP, College Station, TX, USA) was used for Cox analyses.
Results
In total, 221 patients treated with PORT-C for locally advanced
HNSCC were evaluated in this multicentre retrospective study.
Patient characteristics, treatment parameters and the number of
patients included at each of the 8 DKTK partner sites are summa-
rised in Tables 1 and 2.
Isolated loco-regional failure occurred in 21 patients, isolated
distant failure in 31 patients and combined failures were observedin 8 patients. In 2 patients loco-regional recurrence occurred after dis-
tant progression and 4 patients developed distant progression after
loco-regional recurrence. All loco-regional recurrences occurred in
the treatment volume. Actuarial rates at two years for loco-regional
control, freedom from distant metastases and overall survival for
the total patient population were 89.6%, 85.1% and 83.4%.
The results of the biomarker analyses of HPV DNA, p16 and p53
and their occurrence at the different tumour sites are shown in
Table 3. According to the International Agency for Research in
Cancer (IARC), HPV16 DNA positive HNSCC are currently being
considered as HPV associated [23] and only this parameter was
used for further analysis. HPV16 DNA positivity was observed in
34% of the tumours. Overexpression of p16 was found in 37% of
all tumours, and 53% of the oral cavity tumours were positive for
p53. The majority (86%) of HPV16 DNA positive tumours were
found to be p53 negative.
Only two loco-regional recurrences occurred in patients suffer-
ing from HPV16 DNA positive tumours: the ﬁrst in a R0-resected,
ECE positive, pT2 pN2b oral cavity carcinoma (ﬂoor of mouth) after
23 months in the boost volume (66 Gy), the second in a R0
resected, ECE positive pT2 pN2b oropharyngeal cancer (tonsil) after
26 months at the margin of the boost volume (64 Gy) to the adju-
vant volume (54 Gy). Univariate analyses revealed a signiﬁcant
impact on loco-regional tumour control for HPV16 DNA positivity
(HR 0.13; p < 0.01; Fig. 1A, Supplementary Table S1). This effect
was seen at all 8 treatment centres (Fig. 2). Overexpression of
p16 (HR 0.24; p < 0.01), p53 positivity (HR 3.36; p < 0.01) and
tumour site (oral cavity vs. all other tumour sites, HR 3.86;
p < 0.01; oropharynx vs. all other tumour sites, HR 0.38; p = 0.01)
also showed a signiﬁcant impact on loco-regional tumour control.
No signiﬁcant impact was found for sex, UICC stage, R status and
ECE status (Supplementary Table S1). Speciﬁcity and sensitivity
of HPV16 DNA positivity in the total patient population to predict
loco-regional tumour control were 93% and 38%, the corresponding
values for overexpression of p16 were 86% and 41%. In oropharyn-
geal cancer speciﬁcity and sensitivity of HPV16 DNA positivity
were 91% and 53%, for p16 overexpression 73% and 56% were
obtained (1 out of 11 loco-regional recurrences occurred within
the HPV16 DNA positive group, 3 out of 11 were tested positive
for p16). Stratiﬁed for tumour site, univariate analyses in oropha-
ryngeal cancer showed that HPV16 DNA (HR 0.09; p = 0.02;
Fig. 1B, Supplementary Table S1) but not p16 overexpression or
p53 positivity have a signiﬁcant impact on loco-regional tumour
control, whereas p53 showed a signiﬁcant impact on loco-regional
tumour control in oral cavity cancer (HR 3.61; p < 0.05; Supple-
mentary Table S1).
Table 4 summarises the results of the multivariate analyses,
including the signiﬁcant parameters of the univariate analyses plus
ECE status, which had shown a signiﬁcant impact on the secondary
endpoints (Supplementary Table S1). For the total patient popula-
tion, positive HPV16 DNA status was signiﬁcantly associated with
a high chance of loco-regional tumour control (HR 0.20; p = 0.04).
Oral cavity cancer showed signiﬁcantly poorer loco-regional
tumour control than oropharyngeal cancers (HR 2.30; p = 0.04).
Multivariate analysis stratiﬁed for tumour site showed that positive
HPV16 DNA status correlated with loco-regional tumour control in
patients with oropharyngeal carcinoma (HR 0.09; p = 0.03) but not
in the oral cavity carcinoma group (Table 4). As HPV16DNA and p16
are strongly correlated, a second multivariate Cox model assessing
p16 overexpression was performed. The results of this Cox model
showed that the HPV status was a borderline independent prognos-
tic marker for loco-regional tumour control in the total patient pop-
ulation (HR 0.36; p = 0.07; Supplementary Table S2).
Multivariate evaluation of the secondary endpoints in the total
population revealed a signiﬁcant association of HPV16 DNA
positivity with overall survival (HR 0.36; p < 0.01) but not with
Table 1
Patient characteristics and treatment parameter.
Patient characteristic n %
Number of patients 221
Sex Male 180 81.4
Female 41 18.6
UICC stage II 8 3.6
III 33 18.6
IV 180 81.4
Tumour localisation Oral cavity 60 27.1
Oropharynx 126 57.0
Hypopharynx 35 15.8
R status⇑ Negative 125 56.6
Positive 94 42.5
ECE status Negative 102 46.2
Positive 119 53.8
Treatment parameter Median Percentiles Range
10% 25% 75% 90%
Applied cisplatin-dose (mg/m2 body surface area) 200 100 200 200 240 100–300
RT dose (Gy)
Boost volume 64.0 60.0 63.9 66.0 66.0 57.2–68.4
Per fraction 2.0 1.8 1.8 2.0 2.0 1.8–2.1
Adjuvant volume 50.4 50.0 50.0 55.9 60.0 46.8–66.0
Per fraction 2.0 1.8 2.0 2.0 2.1 1.8–2.2
Time between last surgery and ﬁrst radiotherapy (weeks) 6.0 4.1 5.0 7.5 9.6 1.0–23.0
Overall treatment time of PORT-C (days) 44.0 41.0 43.0 46.5 50.0 31.0–57.0
Follow-up time (months) 47.3 11.1 30.7 61.2 71.7 2.5–98.6
* Two patients were not evaluable.
Table 2
Number of patients per treatment centre and tumour localisation.
Treatment centre n Oral cavity Oropharynx Hypopharynx
Dresden 42 21 14 7
Frankfurt 27 12 14 1
Tübingen 33 9 19 5
Freiburg 30 5 20 5
Essen 32 2 22 9
Berlin 24 9 11 4
Municha 17 0 16 1
Heidelberg 15 2 10 3
Total 221 60 126 35
a Partner site Munich consists of Technische Universität and Ludwig-
Maximilians-Universität.
Table 3
Number of tumours with positive biomarkers per tumour localisation.
Biomarker Overall Oral cavity Oropharynx Hypopharynx
HPV16 DNA 72 (33.5%) 7 (12.1%) 59 (48.0%) 5 (14.7%)
HPV16/18 DNAa 1 – 1 –
HPV18 DNA 1 1 – –
HPV33 DNA 1 – 1 –
p16 79 (36.9%) 11 (18.3%) 65 (53.7%) 3 (9.1%)
p53 85 (38.5%) 32 (53.3%) 40 (31.7%) 13 (37.1%)
a Patient was included in HPV16 DNA positive group.
320 HPV16 DNA status and loco-regional control after PORT-C in HNSCCdistant metastases. ECE status showed signiﬁcant association with
distant metastases (HR 2.55; p < 0.01) and borderline signiﬁcance
with overall survival (Table 4 and Supplementary Table S1).
Overexpression of p16 showed a signiﬁcant association with
distant metastases (HR 0.31; p = 0.02) and on overall survival (HR
0.44; p = 0.01) (Supplementary Table S2).
Discussion
While several previous studies provided strong evidence that
the HPV status is a signiﬁcant prognostic marker of loco-regionaltumour control and/or survival in patients treated with primary
radiotherapy or radiochemotherapy for locally advanced HNSCC
[14,16,18,19], the impact of HPV status on outcome of postopera-
tive radio(chemo)therapy is less well investigated. The results of
the present multicentre retrospective study of the DKTK-ROG show
that HPV16 DNA positivity is a signiﬁcant prognosticator of loco-
regional tumour control and survival of patients treated with cis-
platin-based postoperative radiochemotherapy after surgical
resection of locally advanced HNSCC. The effect appears to be
robust over all treatment centres and is driven by the results in
oropharyngeal cancers. Our ﬁndings are in line with a study by
Snietura et al. who investigated the inﬂuence of HPV infection on
the clinical outcome in a posthoc analysis of a randomised clinical
trial of two different schedules of PORT without chemotherapy in
279 HNSCC patients. HPV analysis was conducted in tumours of
131 patients. From the 66 patients with oral cavity or oropharyn-
geal carcinoma, 9 were found to be positive for HPV16 DNA and
were locally controlled after 5 years, whereas the loco-regional
tumour control rate in the whole HPV DNA negative group was
only 58% [24]. Taken together, HPV16 DNA appears to be a poten-
tially promising biomarker for stratiﬁcation and individualised
prescription of postoperative radiotherapy. HPV-positivity seems
to be sufﬁcient to deﬁne a patient cohort that is highly unlikely
to develop loco-regional recurrences after PORT-C, which is in con-
trast to primary radiochemotherapy where more stratiﬁcation
parameters are necessary [25]. This difference between the two
treatment approaches may be caused by the fact that such addi-
tional factors, most obviously tumour volume, play a lesser role
when the tumour is resected. Other patient-related risk factors like
smoking status could not be evaluated in our dataset but might be
relevant as well. We are currently performing similar analyses in a
patient cohort that has been treated by the same centres and
within the same period of time with primary radiochemotherapy
to further evaluate such differential prognosticators using a multi-
dimensional statistical approach including radiobiological esti-
mates e.g., on tumour cell number. For the group of HPV-
negative patients, the situation is largely different. Here, HPV can-
Table 4
Multivariate analyses of prognostic factors for loco-regional control, distant metastases and overall survival. HR = hazard ratio; 95% CI = 95 percent conﬁdence interval.
All sites Oral cavity Oropharynx
HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
Loco-regional control
HPV16 DNA 0.20 (0.04–0.92) 0.04 0.83 (0.10–6.75) 0.87 0.09 (0.01–0.74) 0.03
p53 positivity 1.81 (0.81–4.06) 0.15 3.21 (0.87–11.8) 0.08 0.89 (0.23–3.50) 0.87
ECE status 1.35 (0.62–2.93) 0.45 3.68 (0.83–16.4) 0.09 1.09 (0.29–4.14) 0.90
Oral cavity⇑ 2.30 (1.02–5.16) 0.04 – – – –
Hypopharynx⇑ 0.71 (0.19–2.58) 0.60 – – – –
Distant metastases
HPV16 DNA 0.56 (0.22–1.42) 0.23 0.97 (0.21–4.38) 0.97 0.40 (0.11–1.49) 0.17
p53 positivity 1.39 (0.72–2.70) 0.32 0.93 (0.35–2.45) 0.88 1.46 (0.42–5.12) 0.55
ECE status 2.55 (1.26–5.15) <0.01 9.10 (1.21–68.8) 0.03 1.36 (0.43–4.34) 0.60
Oral cavity⇑ 2.37 (1.11–5.07) 0.03 – – – –
Hypopharynx⇑ 2.73 (1.15–6.47) 0.02 – – – –
Overall survival
HPV16 DNA 0.36 (0.17–0.73) <0.01 0.30 (0.04–2.23) 0.24 0.36 (0.15–0.82) 0.02
p53 positivity 1.07 (0.65–1.79) 0.78 1.27 (0.58–2.79) 0.55 1.03 (0.46–2.30) 0.94
ECE status 1.63 (0.98–2.70) 0.06 3.60 (1.24–10.5) 0.02 0.99 (0.47–2.13) 1.00
Oral cavity⇑ 1.73 (1.00–2.96) <0.05 – – – –
Hypopharynx⇑ 0.66 (0.30–1.46) 0.31 – – – –
* Baseline oropharynx.
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Fig. 1. Kaplan–Meier estimates of loco-regional tumour control. (A) Patients with HPV16 DNA positive HNSCC had signiﬁcantly higher loco-regional tumour control
compared to HPV16 DNA negative tumours. (B) In subgroup analysis, patients with HPV16 DNA positive oropharyngeal tumours showed signiﬁcantly higher loco-regional
tumour control rates than those with HPV16 DNA negative tumours conﬁned to the oropharynx.
4 5
Treatment
centre
Loco-regional control, 
HR (95% CI)
HPV16 DNA positive HPV16 DNA negative
Events Total Events Total
Centre 1 0.23 (0.02-1.80) 1 12 9 30
Centre 2 0 * 0 7 4 20
Centre 3 0 * 0 11 3 20
Centre 4 0 * 0 10 3 20
Centre 5 0 * 0 9 4 23
Centre 6 0 * 0 4 2 17
Centre 7 0.32 (0.02-5.12) 1 13 1 4
Centre 8 0 * 0 6 1 9
Overall 0.13 (0.03-0.54) 2 72 27 143
0 1 2 3
HR (95% CI)
χ²-test of heterogeneity
not significant (p>0.2)
* No CI was calculated in case of no event in the HPV16 DNA positive group
Fig. 2. Forest plot demonstrating the impact of HPV16 DNA status on loco-regional tumour control at the different treatment centres and the pooled estimate (univariate
analyses; Supplementary Table S1). HPV16 DNA status is a prognostic parameter for loco-regional tumour control at all treatment centres.
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322 HPV16 DNA status and loco-regional control after PORT-C in HNSCCnot be used as a sole biomarker to predict tumour recurrences, as
shown by the low sensitivity of 38% or 41% for HPV16 DNA or p16
positivity. Thus, the HPV-negative group needs further investiga-
tions into potential biomarkers to stratify for patients who may
need treatment intensiﬁcation and for patients for whom local
recurrences are not to be expected.
Currently a prospective multicentre study of the DKTK-ROG is
ongoing to validate the prognostic value of HPV16 DNA positivity
on loco-regional tumour control after PORT-C in 240 HNSCC
patients. If the results of the present retrospective cohort are con-
ﬁrmed, an interventional trial to de-escalate PORT-C radiation
doses in HPV16 DNA positive, clinically suitable oropharyngeal
cancer patients will be initiated. Speciﬁcity assessment of HPV16
DNA positivity for loco-regional tumour control from the present
investigation suggests that very few if any recurrences should be
expected from a moderate decrease of radiation dose in these
patients, therefore strict stopping rules for patient safety against
the risk of inferior treatment may be applied in such trial, using
e.g., a Pocock boundary approach [26]. Further reﬁnement of risk
stratiﬁcation speciﬁcally for the HPV-negative group may result
from prospective assessment of clinical parameters [27] in the val-
idation trial, and from ongoing efforts to identify further biomark-
ers in the current retrospective and in the validation patient
cohort.
The low risk of loco-regional recurrence in HPV16 DNA positive
oropharyngeal cancers after curatively intended resection and
PORT-C suggests that either less tumour stem cells are present at
start of PORT-C, that the remaining HPV-positive tumour cells
are more radio(chemo)sensitive, or a combination of both. Recently
it was reported that HPV-positive oropharyngeal cancers show low
expression of stem cell markers such as CD44 and CD98 compared
to HPV-negative oropharyngeal cancers [28]. Furthermore, patients
with HPV-positive and low CD98 expressing tumours showed bet-
ter overall survival and progression-free survival compared to
patients with high CD98 expressing HPV-positive tumours.
Increased radiosensitivity of HPV-positive tumour cells is sup-
ported by a number of investigations. HPV-positive HNSCC cell
lines (all positive for HPV DNA, HPV RNA and p16) assessed by col-
ony formation assay in vitro showed a higher cellular radiosensi-
tivity when compared to HPV-negative cell lines due to
compromised DNA repair capacity [29]. Similar observations have
been reported by others [30,31]. Further observations using both
in vitro and in vivo approaches suggest that overexpressed p16
impairs the recruitment of RAD51 to the DNA damage site in
HPV-positive HNSCC by down-regulation of cyclin D1, thereby
affecting the cell cycle and homologous recombination-mediated
DNA repair response [32].
There is currently no generally agreed consensus for the assess-
ment of the HPV infection status as a potential biomarker; general
methods used for assessment of HPV infection include HPV DNA,
HPV RNA, and p16 overexpression [33–35]. The vast majority of
HPV-positive HNSCC has been shown to be positive for HPV16
DNA [21,36], which is in line with the results reported here.
HPV16 DNA showed stronger correlations with outcome parame-
ters as compared to p16 immunohistochemistry in a cohort of 50
patients with oropharyngeal tumours who received primary radio-
chemotherapy [37]. Also in our study HPV16 DNA appears as a
stronger prognosticator for loco-regional tumour control compared
to p16 expression (Table 4 vs. Supplementary Table S2), however
this needs to be validated in a larger cohort.
In the present study HPV16 DNA positivity was a strong inde-
pendent prognosticator for loco-regional tumour control in oropha-
ryngeal but not in oral cavity tumours. In contrast, increased p53
positivity was observed in oral cavity tumours, which suggests an
alternative pathway for tumour development, e.g. life style factors.The tumour suppressor gene TP53 is known to be involved in carci-
nogenesis of HNSCC [38] and its overexpression is reported in heavy
smokers and heavy drinkers [39,40]. Increased positivity has been
linked to TP53 gene mutations, which can cause stabilisation and
nuclear accumulation of p53 proteins [41]. It has been demon-
strated that the HPV oncoprotein E6 inactivates and inhibits p53
[42,43], which is in line with the fact that the majority of our
HPV-positive study cohort was negative for p53.
In our study, extracapsular extension of lymph nodes is a prog-
nostic factor for overall survival in patients with oral cavity carci-
nomas but not in the total patient population. This seems to be in
contrast to the results of the meta-analysis by Bernier et al., show-
ing that positive margins and/or extracapsular extension are the
most signiﬁcant prognosticators for poor outcome/overall survival
[9]. However this meta-analysis did not stratify between oral cav-
ity and oropharyngeal cancer and molecular biomarkers were not
investigated as confounding factors in the trials included in the
meta-analysis (EORTC and RTOG trials). Furthermore patients
included in the EORTC and RTOG trials might reﬂect a different
population relative to the patient cohort analysed in the present
study, underlining the necessity of constant marker adaptation
for patient stratiﬁcation. Further efforts to investigate different
biomarkers speciﬁcally for the HPV-negative group receiving post-
operative radiochemotherapy as well as for primary radiochemo-
therapy are currently ongoing in the DKTK-ROG using material of
the cohort reported here and of the validation trial.
In conclusion, our results of this retrospective explorative mul-
ticentre study show that HPV16 DNA seems to be a strong prog-
nosticator of loco-regional tumour control after postoperative
cisplatin-based radiochemotherapy of locally advanced oropharyn-
geal carcinoma and is therefore a promising biomarker for patient
stratiﬁcation. The effect appeared robust over the 8 treatment cen-
tres. For patients with HPV16 DNA positive oropharyngeal carci-
noma treatment de-intensiﬁcation may be a valid interventional
option for a prospective trial that is currently prepared.Conﬂict of interest statement
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